"The Report Remicade
(infliximab) (Rheumatoid Arthritis) - Forecast and Market Analysis to
2023 provides information on pricing, market analysis, shares,
forecast, and company profiles for key industry participants. -
MarketResearchReports.biz"
Description
Remicade (infliximab)
(Rheumatoid Arthritis) - Forecast and Market Analysis to 2023
Summary
Rheumatoid arthritis (RA) is a
chronic autoimmune disease which causes inflammation and deformity of
the joints. It affects over seven million individuals in the 10MM
covered in this report (US, France, Germany, Italy, Spain, UK, Japan,
Australia, China, and India) and the prevalence is expected to grow
to just over 8.5 million individuals by 2023. The anti-TNFs have been
effective in treating the signs and symptoms of RA and inhibiting
progression to erosive bone disease. However, the landscape is
quickly changing with the introduction of biosimilars, novel
biologics, and a class of oral therapies known as JAK inhibitors, all
of which will change the market dynamics between 2013 and 2023. With
the anti-TNFs as extremely effective therapies for RA, the market is
extremely competitive for new entrants and will undergo further
pressure as biosimilars are approved and launch.
Remicade (infliximab) was
originally developed as a result of a collaboration between two
professors at NYU Langone Medical Center and Centocor Ortho Biotech
(acquired by Janssen Biotech, a subsidiary of J&J) (NYU Langone
Medical Center, press release, August 12, 2005). It is
first-generation TNF inhibitor consisting of a chimeric IgG1 mAb that
is specific for TNFa. Remicade binds to TNFa with high affinity,
neutralizing the effects of this cytokine, thus preventing synovial
inflammation and decreasing joint erosion in patients with RA.
View
Full Report at http://www.marketresearchreports.biz/analysis/247125
Scope
- Overview of Rheumatoid
Arthritis, including epidemiology, etiology, symptoms, diagnosis,
pathology and treatment guidelines as well as an overview on the
competitive landscape.
- Detailed information on
Remicade (infliximab) including product description, safety and
efficacy profiles as well as a SWOT analysis.
- Sales forecast for Remicade
(infliximab) for the top 10 countries from 2013 to 2023.
- Sales information covered
for the US, France, Germany, Italy, Spain, the UK, Japan, Australia,
China and India.
Reasons
to buy
- Understand and capitalize by
identifying products that are most likely to ensure a robust return.
- Stay ahead of the
competition by understanding the changing competitive landscape for
Rheumatoid Arthritis.
- Effectively plan your M&A
and partnership strategies by identifying drugs with the most
promising sales potential.
- Make more informed business
decisions from insightful and in-depth analysis of Remicade
(infliximab) performance.
- Obtain sales forecast for
Remicade (infliximab) from 2013-2023 in top 10 countries (the US,
France, Germany, Italy, Spain, the UK and Japan, Australia, China and
India).
Download
Detail Report With Complete TOC at
Table
of Content
1 Table of Contents
1 Table of Contents 6
1.1 List of Tables 8
1.2 List of Figures 8
2 Introduction 9
2.1 Catalyst 9
2.2 Related Reports 10
2.3 Upcoming Related Reports
13
3 Disease Overview 14
3.1 Etiology and
Pathophysiology 14
3.1.1 Etiology 14
3.1.2 Pathophysiology 14
3.2 Symptoms 19
3.3 Prognosis 20
3.4 Quality of Life 20
4 Disease Management 21
4.1 Diagnosis and Treatment
Overview 21
4.1.1 Diagnosis 21
4.1.2 Treatment Guidelines 23
4.1.3 Leading Prescribed Drugs
for the Treatment of RA 33
4.1.4 Clinical Practice 34
5 Competitive Assessment 40
5.1 Overview 40
6 Remicade (infliximab) 42
6.1 Overview 42
6.2 Efficacy 44
6.3 Safety 46
6.4 SWOT Analysis 47
6.5 Forecast 47
7 Appendix 49
Browse
Latest News at http://www.marketresearchreports.biz/articles
About
Us
MarketResearchReports.biz is
the most comprehensive collection of market research reports.
MarketResearchReports.Biz services are specially designed to save
time and money for our clients. We are a one stop solution for all
your research needs, our main offerings are syndicated research
reports, custom research, subscription access and consulting
services. We serve all sizes and types of companies spanning across
various industries.
Browse
Our Press Releases by Prnewswire:
http://www.prnewswire.com/news/marketresearchreports.biz
Contact
Us
Office:
State Tower
90 Sate Street, Suite 700
Albany, NY 12207
United States
Tel: +1-518-618-1030
USA: Canada Toll Free:
866-997-4948
No comments:
Post a Comment